Sanofi (SNY) is rated a Strong BUY due to its robust drug pipeline, strong free cash flow, and a promising turnaround under new leadership. The company offers a dividend yield above 5.5% and is undervalued based on its multiples, with projected annualized total returns of 16–20% over the next five years. Recent product launches contributed 14% of Q1 revenue, supported by 80 pipeline products and 23 in mid-to-late stage development, indicating strong future growth potential. Sanofi's strong profitability, solid balance sheet, and focus on rare diseases and acquisitions help mitigate risks from patent expirations and competition.
Sanofi has stopped the phase 3 MOBILIZE clinical trial of riliprubart for treating chronic inflammatory demyelinating polyneuropathy (CIDP) after an interim review showed the study is unlikely to demonstrate sufficient efficacy. No safety concerns we...
HR Tech 2026, scheduled for October 20-22 in Las Vegas, announced its agenda centered on real-world AI implementation, workforce skills, and HR transformation. The event features sessions from leaders at major companies like IFF, Lumen, and Sanofi, c...
Kymera Therapeutics has dosed the first participant in the Phase 1 clinical trial of KT-485, an oral IRAK4 degrader, marking a key milestone under its collaboration with Sanofi. This event triggered a $20 million milestone payment from Sanofi to Kyme...
